Is Zymeworks Inc. (ZYME) a good stock to buy?

Olyth's institutional analysis of ZYME reveals an Altman Z-Score of 11.92 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.11B most recent), help investors decide if ZYME fits their risk profile.

What is the current P/E ratio for ZYME?

As of the latest trading session, Zymeworks Inc. (ZYME) has a trailing P/E ratio of -24.44.

Who is the CEO of Zymeworks Inc.?

The current Chief Executive Officer of Zymeworks Inc. is Kenneth H. Galbraith.

What was ZYME's revenue for the last 5 years?

According to its latest income statements, Zymeworks Inc. reported annual revenues of $0.11B (2025), $0.08B (2024), $0.08B (2023), $0.41B (2022), $0.03B (2021) respectively.

Does ZYME pay a dividend?

Zymeworks Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does ZYME have?

In its latest reporting period, Zymeworks Inc. generated $-0.03B in Free Cash Flow against a total debt load of $0.02B.

What is the Price-to-Book (P/B) ratio of Zymeworks Inc.?

The Price-to-Book (P/B) ratio for Zymeworks Inc. (ZYME) is currently 7.39.

What is the Price-to-Sales (P/S) ratio of ZYME?

Based on trailing twelve-month data, Zymeworks Inc. (ZYME) trades at a Price-to-Sales (P/S) ratio of 18.46.

What is Zymeworks Inc.'s Return on Equity (ROE)?

Zymeworks Inc. (ZYME) has a Return on Equity (ROE) of -26.00%, representing its profitability relative to shareholder equity.

ZYME

Zymeworks Inc. · Healthcare

26.32

3.77%(−1.03)

Close Price

27.54

4.64%(+1.22)

After Hours

Last Updated: — ET

52W L: $9.4052W H: $28.49

ZYME NEWS

globenewswire.com

1d ago

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer

defenseworld.net

4d ago

Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME

Capricorn Fund Managers Ltd purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,022,840 shares of the company's stock, valued at approximately $26,931,000. Zymeworks makes up about 6.5% of

defenseworld.net

4d ago

Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast

Neoleukin Therapeutics (NASDAQ: NLTX - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Institutional and Insider Ownership 52.4% of Neoleukin Therapeutics

globenewswire.com

Apr 1

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026.

globenewswire.com

Mar 30

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).

globenewswire.com

Mar 24

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Needham 25th Annual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 15 at 10:15 am Eastern Time (ET). 2026 Bloom Burton & Co. Healthcare Investor Conference: Zymework's management will participate in one-on-one meetings and present on April 21 in Toronto, ON.

Company Profile

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

299

IPO Date

2017-04-28

Beta

1.20

Websitewww.zymeworks.com↗

Insider Activity

Schayowitz Adam

officer: See Remarks

BUY

76,000 SH @ $0.00

2026-04-09

Schayowitz Adam

officer: See Remarks

BUY

70,000 SH @ $27.35

2026-04-09

Schayowitz Adam

officer: See Remarks

BUY

47,000 SH @ $0.00

2026-04-09

Platshon Scott

officer: EVP, Chief Business Officer

BUY

76,000 SH @ $0.00

2026-04-09

Platshon Scott

officer: EVP, Chief Business Officer

BUY

70,000 SH @ $27.35

2026-04-09

Platshon Scott

officer: EVP, Chief Business Officer

BUY

47,000 SH @ $0.00

2026-04-09

Schayowitz Adam

officer: See Remarks

SELL

0 SH @ $0.00

2026-04-09

Schayowitz Adam

officer: See Remarks

SELL

167,000 SH @ $16.92

2026-04-09

Schayowitz Adam

officer: See Remarks

BUY

76,000 SH @ $0.00

2026-04-09

Schayowitz Adam

officer: See Remarks

BUY

70,000 SH @ $27.35

2026-04-09

Schayowitz Adam

officer: See Remarks

BUY

47,000 SH @ $0.00

2026-04-09

Platshon Scott

officer: EVP, Chief Business Officer

BUY

76,000 SH @ $0.00

2026-04-09

Platshon Scott

officer: EVP, Chief Business Officer

BUY

70,000 SH @ $27.35

2026-04-09

Platshon Scott

officer: EVP, Chief Business Officer

BUY

47,000 SH @ $0.00

2026-04-09

Schayowitz Adam

officer: See Remarks

SELL

0 SH @ $0.00

2026-04-09

Schayowitz Adam

officer: See Remarks

SELL

167,000 SH @ $16.92

2026-04-09